![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Leukemia |
Free Subscription
6 Am J Hematol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Leukemia is free of charge.
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase
Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
Am J Hematol. 2024 Dec 19. doi: 10.1002/ajh.27563.
PubMed
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With
Venetoclax + Hypomethylating Agent.
Am J Hematol. 2024 Dec 13. doi: 10.1002/ajh.27564.
PubMed
Abstract available
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding
Factor Leukemia: A Phase II Clinical Trial.
Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27547.
PubMed
Abstract available
Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of
Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A
Report From the RESIDIAG Study.
Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27553.
PubMed
Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic
Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis
on Behalf of the Chronic Malignancies Working Party of the EBMT.
Am J Hematol. 2025;100:38-51.
PubMed
Abstract available
Mini-consolidations or intermediate-dose cytarabine for the post-remission
therapy of AML patients over 60. A retrospective study from the DATAML and SAL
registries.
Am J Hematol. 2025;100:23-32.
PubMed
Abstract available
Epstein-Barr virus-associated lymphoproliferative disease during remission after
induction therapy with dasatinib in Philadelphia chromosome-positive acute
lymphoblastic leukemia: a case report.
Ann Hematol. 2024 Dec 21. doi: 10.1007/s00277-024-06153.
PubMed
Abstract available
Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute
lymphoblastic leukemia/lymphoma.
Ann Hematol. 2024 Dec 18. doi: 10.1007/s00277-024-06132.
PubMed
Abstract available
Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic
leukemia: insights from droplet digital PCR and flow cytometry.
Ann Hematol. 2024 Dec 13. doi: 10.1007/s00277-024-06126.
PubMed
Abstract available
M1 macrophage-derived exosomes alleviate leukemia by causing mitochondrial
dysfunction.
Ann Hematol. 2024 Dec 12. doi: 10.1007/s00277-024-06138.
PubMed
Abstract available
All-trans retinoic acid potentiates cell death induced by quizartinib in acute
myeloid leukemia with FLT3-ITD mutations.
Ann Hematol. 2024 Dec 11. doi: 10.1007/s00277-024-06089.
PubMed
Abstract available
Analysis of synthetic polymer hydrogel-based generation of leukemia stem cells.
Biochem Biophys Res Commun. 2024;744:151149.
PubMed
Abstract available
Single-cell epigenetic and clonal analysis decodes disease progression in
pediatric acute myeloid leukemia.
Blood. 2024 Dec 11:blood.2024025618. doi: 10.1182/blood.2024025618.
PubMed
Abstract available
Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of
pediatric leukemia initiation.
Blood. 2024 Dec 10:blood.2024024505. doi: 10.1182/blood.2024024505.
PubMed
Abstract available
Genetic predisposition meets cytokine imbalance: the influence of TNF-alpha (-308)
polymorphism and TGF-beta levels in pediatric acute lymphoblastic leukemia in Egypt.
BMC Cancer. 2024;24:1509.
PubMed
Abstract available
Proteomic and metabolomic exploration in relapse acute myeloid leukemia bone
marrow supernatant combined with genetic characteristics.
BMC Cancer. 2024;24:1545.
PubMed
Abstract available
Quantification of the FLT3 internal tandem duplication is a reliable marker for
monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD
mutations.
Bone Marrow Transplant. 2024 Dec 10. doi: 10.1038/s41409-024-02495.
PubMed
Fludarabine melphalan reduced intensity conditioning vs radiation-based
myeloablative conditioning in patients undergoing allogeneic transplantation for
acute myeloid leukemia with measurable residual disease.
Bone Marrow Transplant. 2024 Dec 18. doi: 10.1038/s41409-024-02491.
PubMed
Abstract available
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU
(FBM110) in patients with relapsed/refractory AML undergoing allogeneic
hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute
Leukemia Working Part
Bone Marrow Transplant. 2024 Dec 19. doi: 10.1038/s41409-024-02499.
PubMed
Abstract available
Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli:
Diagnosis, underpinnings for disease classification and future directions.
Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
PubMed
Abstract available
Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and
outcomes in the era of immunotherapy.
Br J Haematol. 2024;205:2234-2247.
PubMed
Abstract available
Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I
mutation or relapsed/refractory disease.
Br J Haematol. 2024;205:2228-2233.
PubMed
Abstract available
Two novel families with RUNX1 variants indicate glycine 168 as a new mutational
hotspot: Implications for FPD/AML diagnosis.
Br J Haematol. 2024;205:2315-2320.
PubMed
Abstract available
The importance of genetic variant cleaners: From patient to wet lab and back to
clinical practice.
Br J Haematol. 2024;205:2122-2124.
PubMed
Abstract available
The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic
lymphocytic leukaemia, leads to RCC1::IRF4 fusion.
Br J Haematol. 2024;205:2321-2326.
PubMed
Abstract available
Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.
Br J Haematol. 2024;205:2153-2162.
PubMed
Abstract available
The discovery of the RCC1::IRF4 Fusion in CLL patients with t(1;6)(p35.3;p25.2)
chromosomal translocation.
Br J Haematol. 2024;205:2125-2127.
PubMed
Abstract available
A new face in the treatment of Philadelphia chromosome-positive acute
lymphoblastic leukaemia.
Br J Haematol. 2024;205:2131-2133.
PubMed
Abstract available
Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide
versus HLA-matched unrelated donors in peripheral blood stem cell transplantation
for acute myeloid leukaemia.
Br J Haematol. 2024;205:2376-2386.
PubMed
Abstract available
Clinical outcomes in patients in any phase of CML treated with ponatinib in
France-Data from the TOPASE observational study.
Br J Haematol. 2024;205:2295-2304.
PubMed
Abstract available
Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A
case report and review of vascular complications in germline GATA2
haploinsufficiency.
Br J Haematol. 2024 Dec 8. doi: 10.1111/bjh.19935.
PubMed
Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine
for recurrent pediatric acute myeloid leukemia (AML).
Cancer Chemother Pharmacol. 2024;95:1.
PubMed
Abstract available
A human-like glutaminase-free asparaginase is highly efficacious in ASNS(low)
leukemia and solid cancer mouse xenograft models.
Cancer Lett. 2024 Dec 19:217404. doi: 10.1016/j.canlet.2024.217404.
PubMed
Abstract available
Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in
Preleukemic Cells.
Cancer Res. 2024;84:4233-4245.
PubMed
Abstract available
Pharmacologic Blockade of a Pioneer Transcription Factor.
Cancer Res. 2024;84:4124-4125.
PubMed
Abstract available
A practice-oriented genome-profiling study for acute myeloid leukemia using the
novel HANDLE system: HM-screen-JAPAN02.
Int J Hematol. 2024 Dec 16. doi: 10.1007/s12185-024-03895.
PubMed
Abstract available
Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and
relapsed acute lymphoblastic leukemia.
Int J Hematol. 2024 Dec 9. doi: 10.1007/s12185-024-03890.
PubMed
Abstract available
Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point
Evaluation for Chronic Lymphocytic Leukemia.
J Clin Oncol. 2024 Dec 12:JCO2401881. doi: 10.1200/JCO-24-01881.
PubMed
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up
of SEQUOIA.
J Clin Oncol. 2024 Dec 8:JCO2402265. doi: 10.1200/JCO-24-02265.
PubMed
Abstract available
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a
Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk
Disease.
J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503.
PubMed
Abstract available
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in
Philadelphia Chromosome-Positive ALL.
J Clin Oncol. 2024;42:4246-4251.
PubMed
Abstract available
Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon
Cancer: CALGB/SWOG 80702 (Alliance).
J Natl Cancer Inst. 2024 Aug 24:djae203. doi: 10.1093.
PubMed
Abstract available
Contributions of Pediatric Hematology/Oncology to the Diagnosis, Treatment, and
Cure of Acute Lymphoblastic Leukemia-Part 2b (Numbers 16 to 20).
J Pediatr Hematol Oncol. 2024 Dec 9. doi: 10.1097/MPH.0000000000002981.
PubMed
Abstract available
Reduced prognostic value of beta-2-microglobulin for time to first treatment in
CLL patients with compromised kidney function.
Leuk Lymphoma. 2024;65:2108-2115.
PubMed
Abstract available
The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the
Minnesota experience.
Leuk Lymphoma. 2024;65:2151-2162.
PubMed
Abstract available
ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of
adult T-cell leukemia.
Leuk Lymphoma. 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875.
PubMed
Abstract available
The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its
ability to identify existing therapeutics that could be repurposed to treat
relapsed or refractory disease.
Leuk Lymphoma. 2024 Dec 17:1-19. doi: 10.1080/10428194.2024.2438800.
PubMed
Abstract available
CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous
leukemia: a University of California Hematologic Malignancies Consortium trial.
Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809.
PubMed
Abstract available
Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two
clones with distinct gene expression pattern.
Leuk Lymphoma. 2024 Dec 17:1-9. doi: 10.1080/10428194.2024.2438804.
PubMed
Abstract available
Recent progress in pathological understanding of adult T-cell leukemia/lymphoma
in the new classification era.
Leuk Res. 2024;148:107634.
PubMed
Abstract available
The increase in the expression of circRNAs may contributes to a poor prognosis in
acute myeloid leukemia: A systematic review and meta-analysis.
Leuk Res. 2024;148:107639.
PubMed
Abstract available
Incidence of Richter transformation of chronic lymphocytic leukemia/small
lymphocytic lymphoma in the targeted therapy era.
Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02492.
PubMed
Allogeneic hematopoietic stem cell transplantation in adult acute myeloid
leukemia with t(16;21)(p11;q22)/FUS::ERG.
Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02495.
PubMed
Growth retardation and adult height in pediatric patients with chronic-phase
chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02488.
PubMed
Prognostic relevance of treatment deviations in children with relapsed acute
lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study.
Leukemia. 2024 Dec 11. doi: 10.1038/s41375-024-02474.
PubMed
Abstract available
Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of
transcription factor TCF4.
Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02470.
PubMed
Relationship between donor source, pre-transplant measurable residual disease,
and outcome after allografting for adults with acute myeloid leukemia.
Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02497.
PubMed
Abstract available
Co-targeting of the thymic stromal lymphopoietin receptor to decrease
immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute
lymphoblastic leukemia.
Leukemia. 2024 Dec 16. doi: 10.1038/s41375-024-02493.
PubMed
Abstract available
Immunoglobulin light chain mutational status refines IGHV prognostic value in
identifying chronic lymphocytic leukemia patients with early treatment
requirement.
Leukemia. 2024 Dec 17. doi: 10.1038/s41375-024-02499.
PubMed
Abstract available
ADAR1 is required for acute myeloid leukemia cell survival by modulating
post-transcriptional Wnt signaling through impairing miRNA biogenesis.
Leukemia. 2024 Dec 19. doi: 10.1038/s41375-024-02500.
PubMed
Abstract available
Hairy-Cell Leukemia. Reply.
N Engl J Med. 2024;391:2388.
PubMed
Hairy-Cell Leukemia.
N Engl J Med. 2024;391:2387-2388.
PubMed
Hairy-Cell Leukemia.
N Engl J Med. 2024;391:2386-2387.
PubMed
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
N Engl J Med. 2024;391:2276.
PubMed
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
N Engl J Med. 2024;391:2275-2276.
PubMed
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
N Engl J Med. 2024;391:2275.
PubMed
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
N Engl J Med. 2024;391:2274-2275.
PubMed
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
N Engl J Med. 2024 Dec 7. doi: 10.1056/NEJMoa2411680.
PubMed
Abstract available
IRX-related homeobox gene MKX is a novel oncogene in acute myeloid leukemia.
PLoS One. 2024;19:e0315196.
PubMed
Abstract available
Thank you for your interest in scientific medicine.